Actively Recruiting
Pulmonary Immune Cell-microbiome Interactions in Acute Respiratory Distress Syndrome: the ILLUMINA-1 Study
Led by Hvidovre University Hospital · Updated on 2025-03-17
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the immune cell populations, activation patterns, cytokine-chemokine environment, and lung microbiome in critically ill intensive care unit patients with acute respiratory distress syndrome (ARDS). The study compares these factors between patients with none-to-mild and moderate-to-severe ARDS, focusing on immune cell behavior in the lungs, including T cell activity and microbiome diversity. The study aims to understand how these elements relate to ARDS severity and progression.
CONDITIONS
Brief Title
Pulmonary Immune Cell-microbiome Interactions in ARDS
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Admitted to the ICU at Hvidovre Hospital
- Intubated within the past 72 hours
- Diagnosis of moderate-to-severe ARDS according to the Berlin definition
- Diagnosis of none-to-mild ARDS according to the Berlin definition
You will not qualify if you...
- ARDS caused by COVID-19
- Absolute contraindications for bronchoscopy
- Untreated malignant arrhythmia
- Documented or suspected intracranial hypertension (intracranial pressure > 15 mmHg)
- One-lung ventilation
- Severe coagulopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 days after intubation
Participants undergo collection of respiratory and blood samples including bronchoalveolar lavage, endotracheal aspirate, oral and nasal swabs within 72 hours after intubation to study immune cell and microbiome interactions in the lungs.
1 visit (in-person)
Duration - 7 to 10 days
Participants who remain intubated are reassessed with repeated sample collections after 7 to 10 days to monitor changes in immune cells and lung microbiome over time.
1 follow-up visit (in-person)
Trial Site Locations
Total: 1 location
1
Hvidovre Hospital, University of Copenhagen
Hvidovre, Denmark, 2650
Actively Recruiting
Research Team
M
MD, PhD, Ronni Plovsing
M
MD Katrine Schneider
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here